Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2021

Design of novel tripyridinophane-based Eu(III) complexes as efficient luminescent labels for bioassays applications[†]

Nadine Leygue, Claude Picard, Pamela Faure, Emmanuel Bourrier, Laurent Lamarque, Jurriaan M. Zwier and Chantal Galaup

Table of contents

| General experimental | p 3 |
|--|------|
| Synthesis of compounds 4 and 11 | p 5 |
| NMR, MS and HPLC chromatograms of selected compounds | P 8 |
| Luminescence spectra and photophysical data for $Eu.L^a$, $Eu.L^b$ and $Eu.L^c$ | p 28 |
| References | p 31 |

General experimental

NMR, IR and Mass analyses

¹H and ¹³C NMR spectra were recorded in commercially-available deuteriated solvents on a Bruker AC300, Bruker advance 400 or Bruker advance 500 spectrometer. Chemical shifts are reported in ppm, with residual protonated solvents as the internal references. IR spectra were recorded on a Nexus ThermoNicolet spectrometers High-Resolution Mass Spectra (HRMS) were recorded on a Xevo G2 QTof Waters or a QStar Elite (AppliedBiosystems, SCIEX) spectrometer operating in a positive ion mode (ESI+).

Chromatography

The analytical HPLC was performed on a Thermo Scientific Spectra system P4000 equipped with a UV 1000 detector (deuterium lamp, 190 - 350 nm). The preparative HPLC was performed on a Shimadzu LC-8A equipped with a Diode array detector Varian ProStar, Various chromatographic systems were employed for analytical and preparative HPLC.

System A: Waters XBridge RP-C18 column, 5 μ m, 19 × 100 mm, flow rate 20 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN), $t = 0 \min 50\%$ B, $t = 17 \min 100\%$ B.

System B: Waters XBridge RP-C18 column, 300 Å, 3.5 μ m, 4.6 × 100 mm, flow rate 1 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN with 0.1% formic acid), *t* = 0 min 5% B, *t* = 15 min 100% B.

System C: Waters XBridge RP-C18 column, 5 μ m, 50 × 150 mm, flow rate 100 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN), $t = 0 \min 15\%$ B, $t = 2 \min 15\%$ B, $t = 20 \min 100\%$ B.

System D: Waters XBridge RP-C18 column, 5 μ m, 19 × 100 mm, flow rate 20 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN), $t = 0 \min 15\%$ B, $t = 2 \min 15\%$ B, $t = 20 \min 100\%$ B.

System E: Waters XBridge C₁₈, 5 μ m, 50 x 150 mm, flow rate 100 mL/min, eluents A (H₂O with triethylammonium acetate 25 mM) – B (CH₃CN), $t = 0 \min 2\%$ B, $t = 17 \min 40\%$ B.

System F: Waters Xbridge C₁₈, 300 Å, 3.5 μ m, 4,6 x 100 mm, flow rate 1 mL/min, eluents A (H₂O with ammonium acetate 5 mM, pH 6.5) – B (CH₃CN),), $t = 0 \min 2\%$ B, $t = 15 \min 40\%$ B.

System G: Waters XBridge C₁₈, 5 μ m, 19 x 100 mm, flow rate 20 mL/min, eluents A (H₂O with triethylammonium acetate 25 mM, pH 6) – B (CH₃CN), *t* = 0 min 2% B, *t* = 17 min 40% B.

Absorption spectroscopy and fluorescence spectroscopy

Absorption measurements were done with a Hewlett Packard 8453 temperature-controlled spectrometer in 10 mm quartz cuvette. Emission, excitation spectra and luminescence decays at room temperature of lanthanide complexes were measured using a Cary Eclipse spectrofluorimeter equipped with a Xenon flash lamp source and a Hamamatsu R928 photomultiplier. At liquid-nitrogen temperature, a LS-50B Perkin-Elmer spectrofluorimeter equipped with a Xenon flash lamp source, a Hamamatsu R928 photomultiplier and the low-temperature accessory n^o L2250136 was used. Excitation spectra were corrected for the excitation light intensity, while emission spectra were corrected for the instrument response. Lifetimes τ (uncertainty \leq 5%) are made by monitoring the decay at a wavelength corresponding to the maximum intensity of the emission spectrum, following pulsed excitation. The luminescence quantum yields (uncertainty \pm 10%) were determined by the method described by Haas and Stein¹ using as standard [Ru(bpy)₃]²⁺ in aerated water ($\Phi = 0.04$)² They were measured according to conventional procedures with diluted solutions (optical density < 0.05).

Stability assessment by fluorescence spectroscopy: A 2 nM stock solution of [Eu.L^a] was prepared in HEPES buffer (0.05 M, 0.1% BSA, pH 7.4). 50 μ L aliquots were added to a Greiner Costar half area 96 well plate. Each well was made up to 100 μ L, by addition of 45 μ L of the buffer solution and 5 μ L of either water or 400 mM aqueous solutions of CaCl₂, MgCl₂, MnCl₂, Na₂EDTA or 8 M KF. For NaN₃, 45 μ L of a 61 mM buffer solution was added and 5 μ L of water. The emission intensity from each well at 620 nm was recorded on a RubyStar (BMG) plate reader using the HTRF set-up using an integration window between 60 and 460 μ s, following excitation with a flash lamp at 320 nm. Each sample preparation was done in triplicate and the mean value of the intensity measurements recorded.

Synthesis of compound 4



Compound 7. To a solution of 4-iodophenol (19.76 g, 90 mmol) and *N*-Boc-3bromopropylamine (25.8 g, 108 mmol) in dry CH₃CN (400 mL) were successively added Cs₂CO₃ (44.1 g, 135 mmol) and NaI (3.38 g 22.6 mmol). The mixture was stirred at 60°C for 24 h, then cooled at room temperature and filtered off. The filtrate was concentrated under vacuum and the crude oil was purified by column chromatography on silica gel (eluent: cyclohexane/EtOAc gradient from 95/5 to 60/40 to yield compound **7** (28.8 g, 85%) as a yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ 7.56 (2H, d, *J* = 8.8Hz), 6.69 (2H, d, *J* = 8.8Hz), 4.74 (1H, bs), 4.00 (2H, t, *J* = 6.0Hz), 3.32 (2H, m), 1.99 (2H, m), 1.46 (9H, s) ppm. ¹³C NMR (CDCl₃, 100 MHz) δ 158.7, 156.0, 138.2, 116.9, 82.8, 79.2, 65.8, 38.05, 29.6, 28.4 ppm. Spectroscopy data are in agreement with those previously reported in the literature.³

Compound 8. A solution of compound **7** (4.0 g, 10.6 mmol) in a mixture of THF (14 mL) and triethylamine (14 mL) was degassed with argon by bubbling for 15 min. To this solution were added trimethylsilylacetylene (4.5 mL, 31.8 mmol), PdCl₂(PPh₃)₂ (740 mg, 1.06 mmol) and CuI (404 mg, 2.1 mmol). The mixture was irradiated with microwaves (100 W) for 30 min, then cooling to room temperature and filtered off over celite. The filtrate was concentrated under vacuum and the crude product was purified by column chromatography (eluent: cyclohexane/EtOAc 90/10 to 80/20) to give compound **8** (3.65 g, 99%) as a beige solid. ¹H NMR (CDCl₃, 400 MHz) δ 7.39 (2H, d, *J* = 8.6Hz), 6.80 (2H, d, *J* = 8.6Hz), 4.73 (1H, bs), 4.01 (2H, t, *J* = 6.0Hz), 3.32 (2H, m), 1.97 (2H, m), 1.44 (9H, s), 0.23 (9H, s) ppm. ¹³C NMR (CDCl₃, 100 MHz) δ 158.9, 155.9, 133.4, 115.3, 114.1, 105.05, 92.4, 79.1, 65.8, 37.8, 29.6, 28.5, 0.02 ppm. Spectroscopy data are in agreement with those previously reported in the literature.³

Compound 4. To a solution of compound **8** (10.0 g, 28.8 mmol) in dry methanol (300 mL) cooled at 0° C was added K₂CO₃ (11.9 g, 86.1 mmol). The solution was stirred at room

temperature for 24 h, then concentrated under vacuum. To the residue were added water (50 mL) and CH₂Cl₂ (200 mL). Layers were decanted and the aqueous layer was extracted with CH₂Cl₂ (2 × 150 mL). Combined organic layers were dried over Na₂SO₄, filtered off and concentrated under vacuum to yield compound **4** (7.8 g, 98%) as a dark oil which was used in the next step without further purification.. ¹H NMR (CDCl₃, 400 MHz) δ 7.44 (2H, d, *J* = 8.8Hz), 6.85 (2H, d, *J* = 8.8Hz), 4.75, 1H, bs), 4.04 (2H, t, *J* = 6.0Hz), 3.35 (2H, m), 3.02 (1H, s), 2.00 (2H, m), 1.46 (9H, s) ppm. ¹³C NMR (CDCl₃, 100 MHz) δ 159.2, 156.0, 133.6, 114.45, 114.2, 83.7, 79.2, 75.9, 65.8, 38.0, 29.4, 28.4 ppm.

Synthesis of compound 11



Compound 14. To a solution of 4-iodophenol (4.4 g, 20 mmol) in acetone 25 mL were added K₂CO₃ (3.6 g, 26 mmol) and methyl bromoacetate (5.7 mL, 60 mmol). The mixture was stirred at 50°C for 12 h. After filtration, the solvent was removed under vacuum. The residue was dissolved in CH₂Cl₂ (50 mL) and the solution was washed with water (50 mL). The organic phase was concentrated under vacuum and the crude product was purified by column chromatography on silica gel (eluent: hexanes/EtOAc 95/05) to yield compound **14** (5.65 g, 97%) as a solid. ¹H NMR (CDCl₃, 400 MHz) δ 7.57 (2H, d, *J* = 8.8Hz), 6.54 (2H, d, *J* = 8.8Hz), 4.60 (2H, s), 3.80 (3H, s) ppm. Spectroscopy data are in agreement with those previously reported in the literature.⁴

Compound 15. It was prepared following literature method.⁵ Yield 65%. ¹H NMR (CDCl₃, 400 MHz) δ 7.46 (2H, d, *J* = 8.8Hz), 6.90 (2H, d, *J* = 8.8Hz), 4.96 (2H, s), 3.68 (3H, s), 0.15 (9H, s) ppm.

Compound 11. To a solution of compound **15** (20 g, 76.2 mmol) in dry CH₂Cl₂ (20 mL) were successively added at 0°C dry MeOH (30 mL) and K₂CO₃ (15.8 g, 114 mmol). The solution

was stirred 15 min at 0°C, then 1 h at room temperature. The resulting mixture was filtered off and concentrated under vacuum. The residue was diluted with CH₂Cl₂ (100 mL) and water (80 mL) was added. Layers were decanted and the aqueous layer was extracted with CH₂Cl₃ (2 × 60 mL). The combined layers were dried over Na₂SO₄, filtered off and concentrated under vacuum to yield compound **11** (12 g, 83%) as a light brown solid which was used in the next step without further purification. ¹H NMR (CDCl₃, 400 MHz) δ 7.45 (2H, d, *J* = 8.0Hz), 6.86 (2H, d, *J* = 8.0Hz), 4.65 (2H, s), 3.82 (3H, s), 3.03 (1H, s) ppm. ¹³C NMR (CDCl₃, 100 MHz) δ 169.0, 158.0, 133.7, 115.4, 114.6, 83.3, 76.3, 65.1, 52.3 ppm. MS (ESI+) *m/z* 191.5 (100%, [M+H]⁺) Spectroscopy data are in agreement with those previously reported in the literature.⁶





Figure S1.¹H NMR (400MHz, CDCl₃) spectrum of compound 3.



Figure S2.¹³C NMR (100MHz, CDCl₃) spectrum of compound 3.



Figure S3.¹H NMR (400MHz, CDCl₃) spectrum of compound 4



Figure S4.¹³C NMR (100MHz, CDCl₃) spectrum of compound 4.



Figure S5.¹H NMR (400MHz, CDCl₃) spectrum of compound 5



Figure S6.¹³C NMR (100MHz, CDCl₃) spectrum of compound 5.



Figure S7.¹H NMR (300MHz, CDCl₃) spectrum of compound 6



Figure S8. J-modulated ¹³C NMR (75MHz, CDCl₃) spectrum of compound 6.



Figure S9. HRMS (ESI+) spectrum of compound 6



Figure S10.¹H NMR (400MHz, CDCl₃) spectrum of compound 10.



Figure S11.¹³C NMR (100MHz, CDCl₃) spectrum of compound 10.



Figure S12.¹H NMR (400MHz, CDCl₃) spectrum of compound 11.



Figure S13.¹³C NMR (100MHz, CDCl₃) spectrum of compound 11.



Figure S14.¹H NMR (400MHz, CDCl₃) spectrum of compound 12.



Figure S15.¹³C NMR (100MHz, CDCl₃) spectrum of compound 12.



Figure S16.¹H NMR (300MHz, CDCl₃) spectrum of compound 13.



Figure S17. J-modulated ¹³C NMR (75MHz, CDCl₃) spectrum of compound 13.



Figure S18. HRMS (ESI+) spectrum of compound 13.



Figure S19.¹H NMR (300MHz, CDCl₃) spectrum of compound 16.



Figure S20. J-modulated ¹³C NMR (75MHz, CDCl₃) spectrum of compound 16.



Figure S21. Infrared (neat) spectrum of compound 16.



Figure S22. HRMS (ESI+) of compound 16.



Figure S23.¹H NMR (500MHz, CD₃OD) spectrum of compound 17.



Figure S24.¹³C NMR (125MHz, CD₃OD) spectrum of compound 17



Figure S25. HPLC chromatogram of compound **17** (Conditions: Waters XBridge RP-C18 column, 300 Å, 3.5 μ m, 4.6 × 100 mm, flow rate 1 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN with 0.1% formic acid), *t* = 0 min 5% B, *t* = 15 min 100% B).



Figure S26. ESI⁺/HRMS spectrum of compound 17.



Figure S27. HPLC chromatogram of compound **18a** (Conditions: Waters XBridge RP-C18 column, 300 Å, 3.5 μ m, 4.6 × 100 mm, flow rate 1 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN with 0.1% formic acid), *t* = 0 min 5% B, *t* = 15 min 100% B).



Figure S28. ESI⁺/HRMS spectrum of compound 18a.



Figure S29. HPLC chromatogram of compound **18b** (Conditions: Waters XBridge RP-C18 column, 300 Å, 3.5 μ m, 4.6 × 100 mm, flow rate 1 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN with 0.1% formic acid), *t* = 0 min 5% B, *t* = 15 min 100% B).



Figure S30. ESI⁺/HRMS spectrum of compound 18b.



Figure S31. HPLC chromatogram of compound **18c** (Conditions: Waters XBridge RP-C18 column, 300 Å, 3.5 μ m, 4.6 × 100 mm, flow rate 1 mL/min, eluents A (H₂O with 0.1% formic acid) – B (CH₃CN with 0.1% formic acid), *t* = 0 min 5% B, *t* = 15 min 100% B).



Figure S32. ESI⁺/HRMS spectrum of compound 18c.



Figure S33. HPLC chromatogram of Eu.L^a (Conditions: Waters Xbridge C₁₈, 300 Å, 3.5 μ m, 4,6 x 100 mm, flow rate 1 mL/min, eluents A (H₂O with ammonium acetate 5 mM, pH 6.5), – B (CH₃CN), *t* = 0 min 2% B, *t* = 15 min 40% B).



Figure S34. ESI⁺/HRMS spectrum (measured and calculated pattern) of Eu.L^a complex



Figure S35. ESI⁺/MS spectrum of compound Eu.L^a-NHS.



Figure S36. Corrected emission spectrum of Eu.L^a (a), Eu.L^b (b) and EuL^c (c) in Tris buffer (pH 7.4) at 298 K, $\lambda_{exc} = 337$ nm, and excitation / emission band passes 5 / 2.5 nm.



Figure S37. Spectral changes of Eu.L^a upon addition of KF. Spectra were recorded in a 0.05 M Phosphate buffer at pH7.0 + 0.1% BSA ($\lambda_{exc} = 337$ nm, excitation and emission band passes 20 and 1.5 nm, respectively). The highest intensity bands were set at 1 to exemplify the changes in the $\Delta J=2$ band.

| | Eu. L ª | Eu. L ^b | Eu.L ^c |
|--|----------------|---------------------------|-------------------|
| $I_{\Sigma \mathrm{F} j} / I_\mathrm{F}$ | 10.1 | 10.1 | 10.1 |
| k _r (s ⁻¹) | 349 | 348 | 348 |
| $k_{obs} (s^{-1})$ | 1470 | 1449 | 1408 |
| $\Phi_{\mathrm{Eu}}(\%)$ | 24.0 | 24.0 | 24.7 |
| η_{sens} (%) | 59.0 | 54.0 | 59.5 |
| Φ_{ov} (%) | 14.0 | 13.0 | 14.7 |
| $\Sigma k_{nr} (s^{-1})$ | 1121 | 1101 | 1060 |

Table S1. Measured and calculated photophysical parameters for Eu.L^a, Eu.L^b and Eu.L^c complexes in Tris buffer (pH 7.4) at 298 K.

References

- 1 Y. Haas and G. Stein, J. Phys. Chem., 1971, 75, 3668-3677.
- 2 H. Ishida, S. Tobita, Y. Hasegawa, R. Katoh and K. Nozaki, *Coord. Chem. Rev.*, 2010, **254**, 2449-2458.
- 3 S. N. Georgiades and J. Clardy, Organic Letters, 2006, 8, 4251-4254.
- 4 L. Escobar, G. Aragay and P. Ballester, Chem. Eur. J., 2016, 22, 13682-13689.
- 5 S. J. Butler, L. Lamarque, R. Pal and D. Parker, Chem. Sci., 2014, 5, 1750-1756.
- 6 Y. He, S. Liu, A. Menon, S. Stanford, E. Oppong, A. M. Gunawan, L. Wu, D. J. Wu, A. M.

Barrios, N. Bottini, A. C. B. Cato and Z.-Y. Zhang, J. Med. Chem., 2013, 56, 4990-5008.